SAVIMS

SAVIMS logo white
Menu

Statistical evidence

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Delta Variant’s Impact on Vaccinated Individuals

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: McCullough, P. (2021, September 20). Scientists: Delta infections of fully vaccinated produce 251 times the viral load. Technocracy News. https://www.technocracy.news/scientists-delta-infections-of-fully-vaccinated-produce-251-times-the-viral-load/ Summary: A recent study indicates that fully vaccinated individuals infected with the Delta variant carry viral loads 251 times higher than those infected with earlier strains of SARS-CoV-2. The research, conducted in a controlled […]

COVID-19, Covid-19 vaccines, Ethics, Excess deaths, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Concerns Surrounding Mass Vaccination and COVID-19 Outcomes

| | COVID-19, Covid-19 vaccines, Ethics, Excess deaths, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Beshir, S. (2021). Concerns surrounding mass vaccination and COVID-19 outcomes. Retrieved from [email link]. Summary: Dr Simon Beshir argues that mass vaccination against COVID-19 has led to spikes in cases and deaths across multiple countries. He claims that these increases correlate with vaccination rollouts, asserting that the vaccines do not show a reduction in

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Shedding of Infectious SARS-CoV-2 Despite Vaccination

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Riemersma, K. K., Haddock, L. A. III, Wilson, N. A., Minor, N., Eickhoff, J., Grogan, B. E., Kita-Yarbro, A., Halfmann, P. J., Segaloff, H. E., Kocharian, A., Florek, K. R., Westergaard, R., Bateman, A., Jeppson, G. E., Kawaoka, Y., O’Connor, D. H., Friedrich, T. C., & Grande, K. M. (2022). Shedding of infectious SARS-CoV-2

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Impact of the SARS-CoV-2 Delta Variant and Vaccine Efficacy

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Tareq, A. M., Bin Emran, T., Dhama, K., Dhawan, M., & Tallei, T. E. (2021). Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic. Human Vaccines & Immunotherapeutics, 17(11), 4126–4127. https://doi.org/10.1080/21645515.2021.1963601 Summary: The article examines the impact of the SARS-CoV-2 delta variant

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Update on SARS-CoV-2 Variants of Concern in England

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Public Health England. (2021). SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 17 (25 June 2021). Retrieved from https://www.gov.uk/phe Summary: The Technical Briefing 17 from Public Health England, dated 25 June 2021, reports on the surveillance of SARS-CoV-2 variants in England. As of that date, there are four variants of

COVID-19, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Viral illnesses

Improved Diagnosis of SARS-CoV-2 Using Nucleoprotein and Spike Protein Fragment in ELISA Tests

| | COVID-19, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Viral illnesses

Reference: De Marco Verissimo, C., O’Brien, C., López Corrales, J., Dorey, A., Cwiklinski, K., Lalor, R., … & Doyle, S. (2021). Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. Epidemiology and Infection, 149, e140, 1–11. https://doi.org/10.1017/S0950268821001308 Summary: The article discusses advancements in diagnosing SARS-CoV-2 through the

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Ethics, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Monitoring the Effectiveness of the Ad26.COV2.S COVID-19 Vaccine in South African Healthcare Workers

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Ethics, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: South African Medical Research Council. (2021). Sisonke Protocol Version 4.4 dated 29 Apr 2021. Summary: The Sisonke Protocol is an open-label, single-arm phase 3B study aimed at evaluating the effectiveness of the Ad26.COV2.S COVID-19 vaccine among healthcare workers in South Africa. This study involves approximately 500,000 healthcare workers aged 18 and older, who will

Ethics, Excess deaths, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines

FDA-Approved Prescription Drugs Withdrawn for Safety Reasons

| | Ethics, Excess deaths, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines

Reference: ProCon.org. (2021). FDA-approved prescription drugs later pulled from the market by the FDA. Retrieved from https://prescriptiondrugs.procon.org/fda-approved-prescription-drugs-later-pulled-from-the-market/ Summary: The article by ProCon.org discusses various prescription drugs that were once FDA-approved but later withdrawn from the market due to safety concerns. The FDA’s role in drug removal is highlighted, emphasising that drugs are typically pulled when

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID Vaccine Safety Concerns: An Analysis

| | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Kirsch, S. (2021). All you need to know about COVID vaccine safety. COVID-19 Early Treatment Fund. Summary: Steve Kirsch, Executive Director of the COVID-19 Early Treatment Fund, argues that COVID vaccines may be responsible for more deaths than they prevent. He estimates over 150,000 excess deaths associated with the vaccines, contrasting this figure with

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Safety and Efficacy of BNT162 RNA-Based COVID-19 Vaccines

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Pfizer. (2020). PF-07302048 (BNT162 RNA-Based COVID-19 vaccines) protocol C4591001. Summary: The document outlines the Phase 1/2/3 clinical trial to evaluate the safety, tolerability, immunogenicity, and efficacy of BNT162 RNA-based COVID-19 vaccines, developed by Pfizer and BioNTech. The trial investigates two vaccine candidates: BNT162b1, encoding the receptor-binding domain (RBD), and BNT162b2, encoding the prefusion spike

Scroll to Top